The purpose of this study is to evaluate the efficacy of APSTZD compared to one active drug and placebo in insomnia treatment.

Inclusion Criteria:

• Participants aged between 18 and 64 years;
• Participants diagnosed with insomnia disorder according to the criteria defined by the DSM-V (1) and who report sleep maintenance disorder;
• Participants who agree not to use alcoholic beverages during the entire treatment period (6 weeks).

Exclusion Criteria:

• Participants with known hypersensitivity to the active ingredients used during the trial or who have exhibited complex sleep behavior after using them;
• Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years;
• Women who are pregnant or breastfeeding, as well as women who have a positive result on a pregnancy test (β-hCG) during the screening period of the trial;
• Participants diagnosed with severe liver failure;